Health

STAT+: Biotech companies are struggling to navigate Trump’s new tariffs

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 08/10/2026, 22:36:26 UTC.

Briefings

A 100% tariff on imported pharmaceuticals took effect at the end of September, leaving many biopharma companies without clear exemption pathways. The Trump administration previously offered MFN deals to reduce tariffs, but agreements now only trigger payment in early 2029, exempting major drugmakers while burdening smaller firms. This creates a significant financial gap for smaller companies that must navigate complex regulatory requirements to avoid penalties.

Key points

• A 100% tariff on imported pharmaceuticals took effect at the end of September, leaving many biopharma companies without clear exemption pathways.
• Agreements to reduce tariffs only trigger payment in early 2029, exempting major drugmakers while burdening smaller firms.

Context

The Trump administration announced a 100% section 232 tariff in April, impacting imports of patented drugs and their active ingredients. Companies that made MFN agreements would have had start paying tariff costs in July, but now aren't on the hook for payment until early 2029, per their agreements.

Limitations

Evidence is limited to the initial announcement and current status of agreements; specific exemption details for smaller firms are not fully detailed, and future payment schedules remain uncertain.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 25/10/2026, 01:53:18 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiavndxtck5spireht4vkt5g4pkms3asw2wzamwvz4umwqlyk24dhu